The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial
Open accessAbstract
Background Depression is common in dementia but the evidence base for appropriate drug treatment is sparse and equivocal. We aimed to assess efficacy and safety of two of the most commonly prescribed drugs, sertraline and mirtazapine, compared with placebo. Methods We undertook the parallel-group, double-blind, placebo-controlled, Health Technology Assessment Study of the Use of Antidepressants for Depression in Dementia (HTA-SADD) trial in participants from old-age psychiatry services in nine centres in England. Participants were eligible if they had probable or possible Alzheimer's disease, depression (lasting ≥4 weeks), and a Cornell scale for depression in dementia (CSDD) score of 8 or more. Participants were ineligible if they were clinically critical (eg, suicide risk), contraindicated to study drugs, on antidepressants, in another trial, or had no carer. The clinical trials unit at King's College London (UK) randomly allocated participants with a computer-generated block randomisation sequence, stratified by centre, with varying block sizes, in a 1:1:1 ratio to receive sertraline (target dose 150 mg per day), mirtazapine (45 mg), or placebo (control group), all with standard care. The primary outcome was reduction in depression (CSDD score) at 13 weeks (outcomes to 39 weeks were also assessed), assessed with a mixed linear-regression model adjusted for baseline CSDD, time, and treatment centre. This study is registered, number ISRCTN88882979 and EudraCT 2006-000105-38.…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A number of experts have challenged the effectiveness of commonly used antidepressant medications in this setting, especially for people with dementia, and questioned their long-term use in people with multiple comorbidities (Banerjee 2011;Snowdon 2010).”
From Psychological therapies for depression in older adults residing in long-term care settings (2024) · cites this paper as Banerjee 2011
In the citing paper
“The two RCTs of aromatherapy both took place in care homes. 43,44”
From Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials (2014) · cites this paper as [44]
In the citing paper
“One large, high-quality blinded study found no immediate or long-term improvement relative to the control group for participants with severe agitation. 44”
From Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials (2014) · cites this paper as [44]
In the citing paper
“Selective serotonin reuptake inhibitors (SSRIs) like citalopram and sertraline have shown modest efficacy,42,43”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [43]
In the citing paper
“(b) antidepressant medication causes severe neurological side effects, which reflect antidepressants interfering with brain function, possibly via altering neurotransmitter systems [29-31]”
From Risk analysis of use of different classes of antidepressants on subsequent dementia: A nationwide cohort study in Taiwan (2017) · cites this paper as [29]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
WARE, J. E., KOSINSKI, M., & KELLER, S. D. (1996) · Medical Care · doi:10.1097/00005650-199603000-00003 · Cited by 17,392
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Mixed-Effects Models in Sand S-PLUS
Pinheiro, J. C., & Bates, D. M. (2000) · Statistics and Computing · doi:10.1007/978-1-4419-0318-1 · Cited by 11,187
Mixed-Effects Models in S and S-PLUS
(2001) · Technometrics · doi:10.1198/tech.2001.s574 · Cited by 9,278
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Relatives of the Impaired Elderly: Correlates of Feelings of Burden
Zarit, S. H., Reever, K. E., & Bach-Peterson, J. (1980) · The Gerontologist · doi:10.1093/geront/20.6.649 · Cited by 5,810
(1988) · NFER-Nelson eBooks · Cited by 5,560
Cornell scale for depression in dementia
Alexopoulos, G. S., Abrams, R. C., Young, R. C., & Shamoian, C. A. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90038-8 · Cited by 2,678
Research works printed but not linked: 1
- Bains, 2002, The efficacy of antidepressants in the treatment of depression in dementia, Cochrane Database Syst Rev, 4, CD003944
Cited by
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Self-citationAssessment and management of behavioral and psychological symptoms of dementia
Kales, H. C., Gitlin, L. N., & Lyketsos, C. G. (2015) · BMJ · doi:10.1136/bmj.h369 · Cited by 1,247
Management of Depression in Older Adults: A Review
Kok, R. M., & Reynolds, C. F. (2017) · JAMA · doi:10.1001/jama.2017.5706 · Cited by 890
Current and future treatments for Alzheimer's disease
Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677
“The trial concluded that the current practice of using these antidepressants, with usual care, for first-line treatment of depression in Alzheimer’s disease should be reconsidered [Banerjee et al. 2011].”
BackgroundDepression in Parkinson disease—epidemiology, mechanisms and management
Aarsland, D., Påhlhagen, S., Ballard, C. G., Ehrt, U., & Svenningsson, P. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.189 · Cited by 593
Self-citation
Metadata
- Authors
- Banerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., Bentham, P., Fox, C., Holmes, C., Katona, C., Knapp, M., Lawton, C., Lindesay, J., Livingston, G., McCrae, N., Moniz-Cook, E., Murray, J., Nurock, S., Orrell, M., O'Brien, J., Poppe, M., Thomas, A., Walwyn, R., Wilson, K., & Burns, A.
- Affiliations
- King's College London (GB)
- University of Manchester (GB)
- University of Birmingham (GB)
- University of East Anglia (GB)
- University of Southampton (GB)
- University College London (GB)
- University of Cambridge (GB)
- University of Leicester (GB)
- Hull York Medical School (GB)
- Alzheimer's Society (GB)
- Newcastle University (GB)
- University of Liverpool (GB)
- Corresponding author
- Banerjee, Sube
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2011-07
- Volume
- 378
- Issue
- 9789
- Pages
- 403-411
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2145846347
- Cited by
- 532
- References
- 41
- Citations by year
- 2026: 14 · 2025: 24 · 2024: 25 · 2023: 16 · 2022: 32 · 2021: 47 · 2020: 25 · 2019: 25 · 2018: 24 · 2017: 41 · 2016: 34 · 2015: 42 · 2014: 50 · 2013: 57 · 2012: 57
- FWCI
- 42.64
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Repository@Hull (Worktribe) (University of Hull) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- American Academy of Neurology
- National Institute for Health and Care Research (04/11/02)
- NIHR Evaluation Trials and Studies Coordinating Centre
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- sertraline, mirtazapine, antidepressants, Alzheimer's disease, treatment efficacy, adverse events, older adults, Cornell Scale for Depression in Dementia, anticholinergic effects, serotonin reuptake inhibitors, atypical antidepressants, caregivers, long-term outcomes, health technology assessment, cost-effectiveness, quality of life
- MeSH terms
- Mirtazapine, Aged, Aged, 80 and over, Alzheimer Disease, Antidepressive Agents, Mental Disorders, Dementia, Depressive Disorder, Double-Blind Method, Female, Humans, Male, Mianserin, Randomized Controlled Trials as Topic, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(11)60830-1
- The paper
- Banerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., Bentham, P., Fox, C., Holmes, C., Katona, C., Knapp, M., Lawton, C., Lindesay, J., Livingston, G., McCrae, N., Moniz-Cook, E., Murray, J., Nurock, S., Orrell, M., . . . Burns, A. (2011). Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(11)60830-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.